Elena Bartoloni

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9467949/publications.pdf

Version: 2024-02-01

173 papers	4,636 citations	94269 37 h-index	118652 62 g-index
175 all docs	175 docs citations	175 times ranked	6037 citing authors

#	Article	IF	Citations
1	Correspondence on â€˜Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registryâ€™ by Gianfrancesco Met al. The impact of cardiovascular comorbidity on COVID-19 infection in a large cohort of rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2023, 82, e159-e159.	0.5	1
2	Correspondence on â€˜Anti-inflammatory therapy for COVID-19 infection: the case for colchicineâ€™. Annals of the Rheumatic Diseases, 2023, 82, e81-e81.	0.5	0
3	Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals. Clinical Reviews in Allergy and Immunology, 2022, 62, 346-353.	2.9	2
4	The facts and fictions of precision medicine in autoimmune diseases: is the machine learning approach the response?. Rheumatology, 2022, 61, 484-485.	0.9	0
5	Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group. European Journal of Internal Medicine, 2022, 96, 60-65.	1.0	12
6	An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations. Clinical Reviews in Allergy and Immunology, 2022, 63, 240-250.	2.9	6
7	Addressing the clinical unmet needs in primary SjÃ¶grenâ€™s Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts. Computational and Structural Biotechnology Journal, 2022, 20, 471-484.	1.9	7
8	Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. Rheumatology, 2022, 62, 243-255.	0.9	12
9	Development and Implementation of the AIDA International Registry for Patients With Still's Disease. Frontiers in Medicine, 2022, 9, 878797.	1.2	9
10	Cardiovascular Involvement in SjÃ¶grenâ€™s Syndrome. Frontiers in Immunology, 2022, 13, .	2.2	8
11	Comment on: Equal rights in autoimmunity: is SjÃ¶gren's syndrome ever â€˜secondaryâ€™?. Rheumatology, 2021, 60, e32-e33.	0.9	1
12	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Expertsâ€™ Consensus. Autoimmunity Reviews, 2021, 20, 102738.	2.5	38
13	Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections. Microorganisms, 2021, 9, 121.	1.6	24
14	Diet in Rheumatoid Arthritis versus Systemic Lupus Erythematosus: Any Differences?. Nutrients, 2021, 13, 772.	1.7	6
15	Peripheral Nervous System Involvement in SjÃ¶grenâ€™s Syndrome: Analysis of a Cohort From the Italian Research Group on SjÃ¶grenâ€™s Syndrome. Frontiers in Immunology, 2021, 12, 615656.	2.2	12
16	Contribution of Janus-Kinase/Signal Transduction Activator of Transcription Pathway in the Pathogenesis of Vasculitis: A Possible Treatment Target in the Upcoming Future. Frontiers in Pharmacology, 2021, 12, 635663.	1.6	15
17	Baseline characteristics of systemic lupus erythematosus patients included in the Lupus Italian Registry of the Italian Society for Rheumatology. Lupus, 2021, 30, 1233-1243.	0.8	3
18	Different clinical presentations of primary SjÃ¶gren's syndrome: Not only a matter of age. Comment on: â€œElderly-onset primary SjÃ¶gren's syndrome focused on clinical and salivary gland ultrasonographic features by Lee et al. Joint Bone Spine. 2021;88:105132â€. Joint Bone Spine, 2021, 88, 105191.	0.8	0

#	Article	IF	Citations
19	Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort. Journal of Autoimmunity, 2021, 124, 102729.	3.0	23
20	Identification of a Novel Serological Marker in Seronegative Rheumatoid Arthritis Using the Peptide Library Approach. Frontiers in Immunology, 2021, 12, 753400.	2.2	2
21	Novel insights on lymphoma and lymphomagenesis in primary SjÃ¶gren's Syndrome. Panminerva Medica, 2021, 63, .	0.2	6
22	Unattended compared to traditional blood pressure measurement in patients with rheumatoid arthritis: a randomised cross-over study. Annals of Medicine, 2021, 53, 2050-2059.	1.5	3
23	Retinal detachment as the first manifestation of systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2021, 39, 924.	0.4	0
24	COVID-19: the new challenge for rheumatologists. One year later. Clinical and Experimental Rheumatology, 2021, 39, 203-213.	0.4	1
25	Traditional and disease-related non-computed variables affect algorithms for cardiovascular risk estimation in SjÃ¶gren's syndrome and rheumatoid arthritis. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
26	Post-COVID-19 syndrome in patients with primary SjÃ¶gren's syndrome after acute SARS-CoV-2 infection. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
27	Adherence to the Mediterranean diet and the impact on clinical features in primary SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
28	One year in review 2021: SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2021, , .	0.4	4
29	Traditional and disease-related non-computed variables affect algorithms for cardiovascular risk estimation in SjÃ¶gren's syndrome and rheumatoid arthritis. Clinical and Experimental Rheumatology, 2021, 39, 107-113.	0.4	5
30	Adherence to the Mediterranean diet and the impact on clinical features in primary SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2021, 39, 190-196.	0.4	6
31	One year in review 2021: SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2021, 39, 3-13.	0.4	35
32	Influence of the age at diagnosis in the disease expression of primary SjÃ¶gren syndrome. Analysis of 12,753 patients from the SjÃ¶gren Big Data Consortium. Clinical and Experimental Rheumatology, 2021, 39, 166-174.	0.4	12
33	COVID-19: the new challenge for rheumatologists. One year later. Clinical and Experimental Rheumatology, 2021, 39, 203-213.	0.4	5
34	Influence of the age at diagnosis in the disease expression of primary SjÃ¶gren syndrome. Analysis of 12,753 patients from the SjÃ¶gren Big Data Consortium.. Clinical and Experimental Rheumatology, 2021, 39 Suppl 133, 166-174.	0.4	0
35	Interplay of antiâ€SSA/SSB status and hypertension in determining cardiovascular risk in primary SjÃ¶grenâ€™s syndrome. Journal of Internal Medicine, 2020, 287, 214-215.	2.7	4
36	COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. Immunologic Research, 2020, 68, 213-224.	1.3	157

#	Article	IF	Citations
37	Hypertension and SARS-CoV-2 infection: is inflammation the missing link?. Cardiovascular Research, 2020, 116, e193-e194.	1.8	5
38	Association Between Glandular Infiltrate and Leukopenia in SjÃ¶gren Syndrome (SS): Data From the Italian Research Group on SS (GRISS). Journal of Rheumatology, 2020, 47, 1840-1841.	1.0	6
39	The Impact of SARS-CoV-2 Outbreak on Primary SjÃ¶gren's Syndrome: An Italian Experience. Frontiers in Medicine, 2020, 7, 608728.	1.2	8
40	Prevention and treatment of autoimmune diseases with plant virus nanoparticles. Science Advances, 2020, 6, eaaz0295.	4.7	22
41	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. Frontiers in Medicine, 2020, 7, 42.	1.2	21
42	Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Realâ€Life Setting. Arthritis and Rheumatology, 2020, 72, 1314-1324.	2.9	58
43	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. Journal of Autoimmunity, 2020, 111, 102468.	3.0	103
44	Colchicine, an anti-rheumatic agent, as aÂpotential compound for the treatment of COVID-19. Reumatologia, 2020, 58, 261-264.	0.5	7
45	COVID-19: the new challenge for rheumatologists. Clinical and Experimental Rheumatology, 2020, 38, 175-180.	0.4	69
46	The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart. Clinical and Experimental Rheumatology, 2020, 38, 580.	0.4	7
47	COVID-19: the new challenge for rheumatologists. First update. Clinical and Experimental Rheumatology, 2020, 38, 373-382.	0.4	15
48	Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases. Clinical and Experimental Rheumatology, 2020, 38, 754-759.	0.4	33
49	One year in review 2020: comorbidities, diagnosis and treatment of primary SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 10-22.	0.4	10
50	The use of digital image analysis in the histological assessment of SjÃ¶gren's syndrome salivary glands improves inter-rater agreement and facilitates multicentre data harmonisation. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 180-188.	0.4	5
51	Characterisation of articular manifestations in primary SjÃ¶gren's syndrome: clinical and imaging features. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 166-173.	0.4	0
52	Significance of anti-La/SSB antibodies in primary SjÃ¶gren's syndrome patients with combined positivity for anti-Ro/SSA and salivary gland biopsy. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 53-56.	0.4	0
53	A Training Tool to support the management and diagnosis of SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 174-179.	0.4	0
54	Systemic phenotype related to primary SjÃ¶gren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 85-94.	0.4	2

#	Article	IF	Citations
55	Validation of thymic stromal lymphopoietin as a biomarker of primary SjÃ¶gren's syndrome and related lymphoproliferation: results in independent cohorts. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 189-194.	0.4	0
56	Different operators and histologic techniques in the assessment of germinal center-like structures in primary SjÃ¶grenâ€™s syndrome minor salivary glands. PLoS ONE, 2019, 14, e0211142.	1.1	11
57	Subclinical Atherosclerosis in Primary SjÃ¶gren's Syndrome: Does Inflammation Matter?. Frontiers in Immunology, 2019, 10, 817.	2.2	24
58	Long-Term Retention Rate of Anakinra in Adult Onset Stillâ€™s Disease and Predictive Factors for Treatment Response. Frontiers in Pharmacology, 2019, 10, 296.	1.6	35
59	Celiac Disease Prevalence Is Increased in Primary SjÃ¶grenâ€™s Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study. Journal of Clinical Medicine, 2019, 8, 540.	1.0	20
60	Th17 Cells. , 2019, , 37-44.		0
61	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. Journal of Clinical Medicine, 2019, 8, 2013.	1.0	118
62	The dark side of SjÃ¶gren's syndrome: the possible pathogenic role of infections. Current Opinion in Rheumatology, 2019, 31, 505-511.	2.0	16
63	Platelets: a potential target for rheumatoid arthritis treatment?. Expert Review of Clinical Immunology, 2019, 15, 1-3.	1.3	8
64	Effect of Sinovial High-LowÂ® injections in trapeziometacarpal osteoarthritis. Clinical and Experimental Rheumatology, 2019, 37, 166.	0.4	4
65	Systemic manifestations of primary SjÃ¶gren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 97-106.	0.4	6
66	One year in review 2019: SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 3-15.	0.4	16
67	The kaleidoscope of neurological manifestations in primary SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 192-198.	0.4	9
68	Application of artificial neural network analysis in the evaluation of cardiovascular risk in primary SjÃ¶gren's syndrome: a novel pathogenetic scenario?. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 133-139.	0.4	3
69	A Platelet's Guide to Synovitis. Israel Medical Association Journal, 2019, 21, 454-459.	0.1	1
70	Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases. Nature Reviews Cardiology, 2018, 15, 33-44.	6.1	50
71	Targeting Inflammation to Prevent Cardiovascular Disease in Chronic Rheumatic Diseases: Myth or Reality?. Frontiers in Cardiovascular Medicine, 2018, 5, 177.	1.1	14
72	Extra-articular rheumatoid arthritis. Reumatismo, 2018, 70, 212-224.	0.4	61

#	Article	IF	Citations
73	Prevalence and significance of anti-saccharomyces cerevisiae antibodies in primary SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 73-79.	0.4	2
74	The prevalence and relevance of traditional cardiovascular risk factors in primary SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 113-120.	0.4	10
75	One year in review 2018: SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 14-26.	0.4	10
76	How immunological profile drives clinical phenotype of primary SjÃ¶gren's syndrome at diagnosis: analysis of 10,500 patients (SjÃ¶gren Big Data Project). Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 102-112.	0.4	37
77	Discrepancy between subjective symptoms, objective measures and disease activity indexes: the lesson of primary SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 210-214.	0.4	5
78	Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. Clinical Reviews in Allergy and Immunology, 2017, 52, 71-80.	2.9	60
79	Relevance of Interferonâ€Inducible Proteinâ€16 Rather than Antiâ€"Interferonâ€Inducible Proteinâ€16 Autoantibodies as a Clinical and Pathogenic Biomarker in Primary SjÃ¶gren's Syndrome: Comment on the Article by Baer et al. Arthritis Care and Research, 2017, 69, 453-454.	1.5	0
80	Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study. Autoimmunity Reviews, 2017, 16, 253-257.	2.5	46
81	Cryoglobulinemia in SjÃ¶gren Syndrome: A Disease Subset that Links Higher Systemic Disease Activity, Autoimmunity, and Local B Cell Proliferation in Mucosa-associated Lymphoid Tissue. Journal of Rheumatology, 2017, 44, 1179-1183.	1.0	33
82	Role of Inflammatory Diseases in Hypertension. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 353-361.	1.0	11
83	Platelets Contribute to the Accumulation of Matrix Metalloproteinase Type 2 in Synovial Fluid in Osteoarthritis. Thrombosis and Haemostasis, 2017, 117, 2116-2124.	1.8	20
84	AB0191â€...Clinical significance of multiple autoantibody specificities in rheumatoid arthritis: the role of anti-citrullinated alpha enolase and anti-interferon inducible protein 16. , 2017, , .		0
85	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Stillâ€™s Disease: A Multicentre Retrospective Observational Study. Frontiers in Pharmacology, 2017, 8, 369.	1.6	89
86	The clinical spectrum of primary SjÃ¶grenâ€™s syndrome: beyond exocrine glands. Reumatismo, 2017, 69, 93.	0.4	15
87	Insulin-Like Growth Factor Binding Protein 6 in Rheumatoid Arthritis: A Possible Novel Chemotactic Factor?. Frontiers in Immunology, 2017, 8, 554.	2.2	28
88	Correlation between ESSDAI and ClinESSDAI in a real-life cohort of patients with SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2017, 35, 546-547.	0.4	3
89	Novel Therapeutic Strategies in Primary SjÃ¶gren's Syndrome. Israel Medical Association Journal, 2017, 19, 576-580.	0.1	3
90	THU0341â€...Correlation between Essdai and Clinessdai in A Real-Life Cohort of SjÃ¶gren's Syndrome Patients: Table 1. Annals of the Rheumatic Diseases, 2016, 75, 310.2-310.	0.5	1

#	Article	IF	Citations
91	The onset site of rheumatoid arthritis: the joints or the lung?. Reumatismo, 2016, 68, 167-175.	0.4	5
92	T Cells in the Pathogenesis of SjÃ¶grenâ€™s Syndrome. , 2016, , 205-215.		0
93	Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary SjÃ¶gren's syndrome: a pilot study. Clinical and Experimental Immunology, 2016, 184, 284-292.	1.1	32
94	Rheumatoid factor in SjÃ¶gren's syndrome: The need to target MALT tissue for preventing lymphoma. Arthritis and Rheumatology, 2016, 68, n/a-n/a.	2.9	4
95	Circulating Interferonâ€Inducible Protein IFI16 Correlates With Clinical and Serological Features in Rheumatoid Arthritis. Arthritis Care and Research, 2016, 68, 440-445.	1.5	24
96	AB0592â€…Evaluation of Arterial Stiffness in A Cohort of Systemic Sclerosis Patients: A Case-Control Study. Annals of the Rheumatic Diseases, 2016, 75, 1107.1-1107.	0.5	0
97	Central Hemodynamics and Arterial Stiffness in Systemic Sclerosis. Hypertension, 2016, 68, 1504-1511.	1.3	17
98	Defining disease activity states and clinically meaningful improvement in primary SjÃ¶gren's syndrome with EULAR primary SjÃ¶gren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Annals of the Rheumatic Diseases, 2016, 75, 382-389.	0.5	225
99	SAT0290â€…A Higher Disease Activity in Anti-Ssa/ssb Positive SjÃ¶gren's Syndrome Is Explained by A Higher Clinical and Biological B-Cell Activation: Table 1. Annals of the Rheumatic Diseases, 2016, 75, 773.2-773.	0.5	0
100	One year in review 2016: SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2016, 34, 161-71.	0.4	26
101	FRI0180â€…Correlation Between Clinimetric Approach and German US7 Score in Rheumatoid Arthritis Patients Treated with Tocilizumab: A Pilot Study. Annals of the Rheumatic Diseases, 2015, 74, 489.1-489.	0.5	0
102	Erratum to â€œls minor salivary gland biopsy more than a diagnostic tool in primary SjoÂ¨grenâ€™s syndrome? Association between clinical, histopathological, and molecular features: A retrospective studyâ€•[Semin Arthritis Rheum 44 (2014) 314â€“324]. Seminars in Arthritis and Rheumatism, 2015, 44, e23.	1.6	0
103	Interferon gamma-inducible protein 16 in primary SjÃ¶grenâ€™s syndrome: a novel player in disease pathogenesis?. Arthritis Research and Therapy, 2015, 17, 208.	1.6	23
104	FRI0024â€…Interferon Gamma-Inducible Protein 16 (IFI16) in Rheumatoid Arthritis: A Novel Biomarker for Pulmonary Involvement?. Annals of the Rheumatic Diseases, 2015, 74, 427.1-427.	0.5	1
105	THU0393â€…IL-17 Producing Pathogenic T Lymphocytes Co-Express CD20 and are Depleted by Rituximab in Primary sjÃ¶gren's Syndrome: A Novel Target for an Old Weapon. Annals of the Rheumatic Diseases, 2015, 74, 339.1-339.	0.5	0
106	Cardiovascular disease risk burden in primary SjÃ¶gren's syndrome: results of a populationâ€based multicentre cohort study. Journal of Internal Medicine, 2015, 278, 185-192.	2.7	110
107	Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome. Medicine (United States), 2015, 94, e1144.	0.4	133
108	AB0564â€…Disease Damage is Associated with Increased Aortic Stiffness in Systemic Lupus Erythematosus: A Cross-Sectional Study. Annals of the Rheumatic Diseases, 2015, 74, 1088.3-1088.	0.5	0

#	Article	IF	Citations
109	Interferon gamma-inducible protein 16 (IFI16) and anti-IFI16 antibodies in primary SjÃ¶grenâ€™s syndrome: findings in serum and minor salivary glands. Reumatismo, 2015, 67, 85-90.	0.4	11
110	Plant-Derived Chimeric Virus Particles for the Diagnosis of Primary SjÃ¶gren Syndrome. Frontiers in Plant Science, 2015, 6, 1080.	1.7	19
111	T Regulatory and T Helper 17 Cells in Primary SjÃ¶grenâ€™s Syndrome: Facts and Perspectives. Mediators of Inflammation, 2015, 2015, 1-10.	1.4	59
112	SAT0377â€...Interferon Gamma-Inducible Protein 16 (IFI16) in Primary SjÃ–gren's Syndrome: A Novel Player in Disease Pathogenesis?. Annals of the Rheumatic Diseases, 2015, 74, 795.4-796.	0.5	0
113	EULAR Sjogren's syndrome disease activity index (ESSDAI): a user guide. RMD Open, 2015, 1, e000022-e000022.	1.8	229
114	Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis. Expert Opinion on Biological Therapy, 2015, 15, 1727-1737.	1.4	29
115	A8.6â€...A novel therapeutic approach in systemic rheumatic autoimmune disorders: encapsulated human umbilical cord wharton jelly-derived mesenchymal stem cells. Annals of the Rheumatic Diseases, 2015, 74, A83.2-A83.	0.5	0
116	Anti-SSA/SSB-negative SjÃ¶gren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmunity Reviews, 2015, 14, 1019-1022.	2.5	80
117	Altered Immunoregulation in Rheumatoid Arthritis: The Role of Regulatory T Cells and Proinflammatory Th17 Cells and Therapeutic Implications. Mediators of Inflammation, 2015, 2015, 1-12.	1.4	208
118	Anticyclic Citrullinated Peptide Antibodies in Patients with Rheumatic Diseases other than Rheumatoid Arthritis: Clinical or Pathogenic Significance?. Journal of Rheumatology, 2015, 42, 1063-1064.	1.0	1
119	A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary SjÃ¶grenâ€™s syndrome. Lupus, 2015, 24, 315-320.	0.8	63
120	Validation of EULAR primary SjÃ¶gren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Annals of the Rheumatic Diseases, 2015, 74, 859-866.	0.5	193
121	Characterization of circulating endothelial microparticles and endothelial progenitor cells in primary Sjogren's syndrome: new markers of chronic endothelial damage?. Rheumatology, 2015, 54, 536-544.	0.9	45
122	Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary SjÃ¶gren's syndrome: results of a large multicentre study. Scandinavian Journal of Rheumatology, 2015, 44, 36-41.	0.6	51
123	In vitro immunomodulatory effects of microencapsulated umbilical cord Wharton jelly-derived mesenchymal stem cells in primary SjÃ¶grenâ€™s syndrome. Rheumatology, 2015, 54, 163-168.	0.9	45
124	Cardiovascular disease in systemic sclerosis. Annals of Translational Medicine, 2015, 3, 8.	0.7	34
125	Serum interleukin-17 in primary SjÃ¶gren's syndrome: association with disease duration and parotid gland swelling. Clinical and Experimental Rheumatology, 2015, 33, 129.	0.4	15
126	One year in review 2015: SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2015, 33, 259-71.	0.4	30

#	Article	IF	Citations
127	Correlation between clinimetric approach and German US7 score in rheumatoid arthritis patients treated with tocilizumab: a pilot study. Clinical and Experimental Rheumatology, 2015, 33, 445.	0.4	0
128	Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. Clinical and Experimental Rheumatology, 2015, 33, 449-56.	0.4	55
129	Myositis in primary SjÃ¶gren's syndrome: data from a multicentre cohort. Clinical and Experimental Rheumatology, 2015, 33, 457-64.	0.4	27
130	A3.1â€…Pathogenic role of IL-17 producing double negative (DN) T cells in primary sjÃ¶grenâ€™s syndrome. Annals of the Rheumatic Diseases, 2014, 73, A42.1-A42.	0.5	0
131	A3.8â€…Association between clinical, histopathological and molecular features in primary SjÃ¶grenâ€™s Syndrome: a retrospective study. Annals of the Rheumatic Diseases, 2014, 73, A45.1-A45.	0.5	0
132	Expansion of regulatory GITR+CD25low/-CD4+ T cells in systemic lupus erythematosus patients. Arthritis Research and Therapy, 2014, 16, 444.	1.6	47
133	Drugs in induction and treatment of idiopathic inflammatory myopathies. Autoimmunity Highlights, 2014, 5, 95-100.	3.9	6
134	THU0194â€…Role of Platelets in the Pathogenesis of Osteoarthritis and Biological Effects of Hyaluronic Acid: in Vivo and in Vitro Study. Annals of the Rheumatic Diseases, 2014, 73, 248.3-249.	0.5	1
135	Primary SjÃ¶grenâ€™s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology, 2014, 53, 839-844.	0.9	185
136	CD4âˆ’CD8âˆ’ T-cells in primary SjÃ¶gren's syndrome: Association with the extent of glandular involvement. Journal of Autoimmunity, 2014, 51, 38-43.	3.0	60
137	Diagnosis and classification of autoimmune hypophysitis. Autoimmunity Reviews, 2014, 13, 412-416.	2.5	72
138	Unmasking the pathogenic role of IL-17 axis in primary SjÃ¶gren's syndrome: A new era for therapeutic targeting?. Autoimmunity Reviews, 2014, 13, 1167-1173.	2.5	36
139	Rituximab in primary SjÃ¶gren's syndrome: a ten-year journey. Lupus, 2014, 23, 1337-1349.	0.8	21
140	The classification criteria for SjÃ¶gren syndrome: issues for their improvement from the study of a large Italian cohort of patients. Annals of the Rheumatic Diseases, 2014, 73, e35-e35.	0.5	6
141	The role of T helper 17 cell subsets in SjÃ¶gren's syndrome: similarities and differences between mouse model and humans. Annals of the Rheumatic Diseases, 2014, 73, e42-e42.	0.5	6
142	Is minor salivary gland biopsy more than a diagnostic tool in primary SjoÂ¨gren×³s syndrome? Association between clinical, histopathological, and molecular features: A retrospective study. Seminars in Arthritis and Rheumatism, 2014, 44, 314-324.	1.6	61
143	SAT0030â€…Circulating Endothelial Microparticles and Endothelial Progenitors Cells in Primary SjÃ–Gren's Syndrome: New Markers of Chronic Endothelial Damage?. Annals of the Rheumatic Diseases, 2014, 73, 599.3-600.	0.5	0
144	Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study. Arthritis Research and Therapy, 2013, 15, R16.	1.6	60

#	Article	IF	Citations
145	Cardiovascular Risk in Rheumatoid Arthritis and Systemic Autoimmune Rheumatic Disorders: a Suggested Model of Preventive Strategy. Clinical Reviews in Allergy and Immunology, 2013, 44, 14-22.	2.9	19
146	The Microbial Capsular Polysaccharide Galactoxylomannan Inhibits IL-17A Production in Circulating T Cells from Rheumatoid Arthritis Patients. PLoS ONE, 2013, 8, e53336.	1.1	13
147	Outcome of Pregnancy in Italian Patients with Primary SjÃ¶gren Syndrome. Journal of Rheumatology, 2013, 40, 1143-1147.	1.0	32
148	Unusual Bursal Fluid. New England Journal of Medicine, 2013, 369, 1945-1945.	13.9	1
149	Characterization of a new regulatory CD4+ T cell subset in primary Sjogren's syndrome. Rheumatology, 2013, 52, 1387-1396.	0.9	63
150	IL-17-producing CD4^{â^'}CD8^{â^'}T cells are expanded in the peripheral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary SjÃ¶gren's syndrome. Annals of the Rheumatic Diseases, 2013, 72, 286-292.	0.5	88
151	SAT0398â€...Diagnostic value of anti mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: A multicentric study by firma group. Annals of the Rheumatic Diseases, 2013, 71, 607.1-607.	0.5	1
152	AB0037â€...CD4+CD25-GITR+regulatory T cells are expanded in the blood, display suppressive function and are inversely correlated with disease activity in patients with primary SjÃ¶grenâ€™s syndrome. Annals of the Rheumatic Diseases, 2013, 71, 639.12-639.	0.5	0
153	FRI0282â€...Serological biomarkers of b-cell lymphoproliferative disorders in patients with primary sjÃ¶grenâ€™s syndrome: retrospective study in a large italian cohort. Annals of the Rheumatic Diseases, 2013, 72, A469.3-A470.	0.5	0
154	SAT0219â€...Prevalence and predictive role of traditional cardiovascular risk factors in a cohort of sjÃ¶grenâ€™s syndrome patients. Annals of the Rheumatic Diseases, 2013, 71, 546.1-546.	0.5	0
155	FRI0001â€...IL-17 producing-DN T cells are expanded in the blood, infiltrate salivary glands and are resistant to corticosteroids in sjÃ–grenâ€™s syndrome. Annals of the Rheumatic Diseases, 2013, 71, 311.1-311.	0.5	1
156	THU0192â€...Myositis in primary sjÃ¦grenâ€™s syndrome: Data from a multicenter cohort. Annals of the Rheumatic Diseases, 2013, 71, 220.2-220.	0.5	0
157	THU0129â€...Selective elimination of pathogenic TH17 cells from peripheral blood of rheumatoid arthritis patients by a purified fungal polysaccharide. Annals of the Rheumatic Diseases, 2013, 71, 198.3-198.	0.5	0
158	AB0952â€...Intra-articular low molecular weight hyaluronate reduces platelet influx and matrix metalloproteinase-2 levels in synovial fluid of patients with knee osteoarthritis. Annals of the Rheumatic Diseases, 2013, 71, 693.3-693.	0.5	0
159	THU0174â€...Endothelial microparticles and circulating endothelial progenitor cells in primary sjÃ¦grenâ€™s syndrome patients: A potential marker of endothelial damage?. Annals of the Rheumatic Diseases, 2013, 71, 214.2-214.	0.5	0
160	SAT0187â€...Immunomodulatory effects of human umbilical cord wharton jelly-derived mesenchymal stem cells (HUCMS) on circulating T-cell subsets in patients with sjÃ¶grenâ€™s syndrome. Annals of the Rheumatic Diseases, 2013, 71, 534.3-535.	0.5	0
161	A3.4â€...CD3⁺CD4^{â€“}CD8^{â€“}Double Negative Th17 Cells: New Insights in the Pathogenesis of Primary SjÃ¶grenâ€™s Syndrome. Annals of the Rheumatic Diseases, 2013, 72, A14.2-A15.	0.5	0
162	SAT0212â€...Pregnancy and fetal outcome in patients with an established diagnosis of primary sjÃ¶grenâ€™s syndrome. Annals of the Rheumatic Diseases, 2013, 71, 543.3-544.	0.5	0

#	Article	IF	Citations
163	Balance between Regulatory T and Th17 Cells in Systemic Lupus Erythematosus: The Old and the New. Clinical and Developmental Immunology, 2012, 2012, 1-5.	3.3	127
164	Beneficial Cardiovascular Effects of Low-dose Glucocorticoid Therapy in Inflammatory Rheumatic Diseases. Journal of Rheumatology, 2012, 39, 1758.2-1760.	1.0	7
165	Aortic stiffness is increased in polymyalgia rheumatica and improves after steroid treatment. Annals of the Rheumatic Diseases, 2012, 71, 1151-1156.	0.5	33
166	Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: An Italian multicentric study and review of the literature. Autoimmunity Reviews, 2012, 11, 815-820.	2.5	48
167	Ultrasound revealing subclinical enthesopathy at the greater trochanter level in patients with spondyloarthritis. Clinical Rheumatology, 2012, 31, 463-468.	1.0	8
168	Increased levels of circulating DNA in patients with systemic autoimmune diseases: A possible marker of disease activity in SjÃ¶grenâ€™s syndrome. Lupus, 2011, 20, 928-935.	0.8	48
169	Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: Two faces of the same coin. Arthritis Care and Research, 2011, 63, 178-183.	1.5	88
170	Role of regulatory T cells in rheumatoid arthritis: facts and hypothesis. Autoimmunity Highlights, 2010, 1, 45-51.	3.9	17
171	How early is the atherosclerotic risk in rheumatoid arthritis?. Autoimmunity Reviews, 2010, 9, 701-707.	2.5	47
172	Cardiac involvement in systemic rheumatic diseases: An update. Autoimmunity Reviews, 2010, 9, 849-852.	2.5	65
173	Atherosclerotic vascular damage and rheumatoid arthritis: a complex but intriguing link. Expert Review of Cardiovascular Therapy, 2010, 8, 1309-1316.	0.6	14